Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact
New Deal Could Be Worth Over $2.3bn
Executive Summary
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
You may also be interested in...
Finance Watch: 14 Biopharma IPOs In One Remarkable Month
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Coronavirus Update: Amid Fears Of Trump Pressure, Fauci Warns Of Rushing Vaccine Authorization
Anthony Fauci says a hasty emergency use authorization for a vaccine would be a mistake - and the FDA commissioner will not be drawn on timelines.
Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy
Fast and furious and slow and steady may both be winning strategies in the race to protect the populace from COVID-19, said Sanofi’s Paul Hudson and John Reed, as the firm accelerated the timeline for its recombinant protein-based vaccine in development with GSK.
Need a specific report? 1000+ reports available
Buy Reports